0EVI.L - Innate Pharma S.A.
| Previous close | 2.9840 |
| Open | 2.9960 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 3.0240 - 3.1180 |
| 52-week range | 3.0240 - 3.1180 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 1.939M |
| Beta (5Y monthly) | 0.32 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6640 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireInnate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR’579 / IPH6101 in R/R AML
MARSEILLE, France, May 26, 2023--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced today that the abstract entitled "A first-in-human study of CD123 NK Cell Engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia or high risk-myelodysplasia" was published on the ASCO 2023 Annual Meeting website. The abstract concludes that SAR’579, in development by Sanofi, was well tolerated up to doses of 3 mg/kg QW with o
Business WireInnate Pharma to Participate in Upcoming Investor Conferences
MARSEILLE, France, May 23, 2023--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that members of its senior management team are scheduled to participate in the following upcoming conferences:
Business WireInnate Pharma to Present IPH6501 Preclinical Data at The EHA 2023 Congress
MARSEILLE, France, May 15, 2023--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that new preclinical data on its IPH6501 tetra-specific ANKET® (Antibody-based Natural Killer cell Engager Therapeutics) have been selected for oral presentation at the European Hematology Association (EHA) 2023 congress, being held 8 to 15 June 2023 in Frankfurt, Germany.
Business WireOutcome of Innate Pharma’s 2023 Annual General Meeting
MARSEILLE, France, May 12, 2023--Outcome of Innate Pharma’s 2023 Annual General Meeting
Business WireInnate Pharma Reports First Quarter 2023 Financial Results and Business Update
MARSEILLE, France, May 10, 2023--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today reported its consolidated financial results for the quarter ending March 31, 2023.
Business WireNumber of shares and voting rights of Innate Pharma as of May 1, 2023
MARSEILLE, France, May 09, 2023--Regulatory News: Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") releases its total number of shares outstanding as well as its voting rights as at May 1, 2023:
Business WireInnate Pharma Highlights Clinical Abstracts Selected for ASCO 2023 Annual Meeting
MARSEILLE, France, May 03, 2023--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced today three abstracts including Innate’s product candidates have been accepted for the American Society for Clinical Oncology (ASCO) 2023 Annual Meeting, taking place June 2-6, 2023 in Chicago, IL.
Business WireInnate Pharma Announces Conference Call and Webcast for Q1 Business Update
MARSEILLE, France, May 03, 2023--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Wednesday, May 10, 2023 at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first quarter of 2023.
Business WireInnate Pharma Establishes a New At-The-Market ("ATM") Program on Nasdaq
MARSEILLE, France, April 26, 2023--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that it has filed a prospectus supplement with the Securities and Exchange Commission ("SEC") relating to a new At-The-Market ("ATM") program. Pursuant to this program, the Company may offer and sell to eligible investors (as described below) a total gross amount of up to $75 million of American Depositary Shares ("ADS"), each ADS representing one ordinary share of
Business WireInnate Pharma to Participate in Upcoming Investor Conference
MARSEILLE, France, April 21, 2023--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that members of its senior management team are scheduled to participate in the following upcoming investor conference:
Business WireNumber of Shares and Voting Rights of Innate Pharma as of April 1, 2023
MARSEILLE, France, April 18, 2023--Regulatory News: Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") releases its total number of shares outstanding as well as its voting rights as at April 1, 2023:
Business WireInnate Pharma to Hold Its Annual General Meeting of Shareholders on May 12, 2023
MARSEILLE, France, April 07, 2023--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") will hold its Annual General Meeting of Shareholders ("AGM") at 10:30 a.m. CEST on May 12, 2023 in its headquarters, 117 avenue de Luminy, F-13009 Marseille. The Annual General Meeting will be broadcasted live.
Business WireInnate Pharma Files Its 2022 Universal Registration Document (Document d’enregistrement universel) and 2022 Annual Report on Form 20-F
MARSEILLE, France, April 06, 2023--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced the filing of its 2022 Universal Registration Document (Document d’enregistrement universel) for the year ending December 31, 2022 with the French market authority "Autorité des Marchés Financiers" ("AMF") on April 6, 2023. It can be downloaded (in French) on the Company’s website and on the AMF’s website.
Business WireInnate Pharma Announces Exclusive License of Antibodies to Takeda for Celiac Disease Research Program
MARSEILLE, France, April 03, 2023--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) today announced that it has entered into an exclusive license agreement with Takeda under which Innate grants Takeda exclusive worldwide rights to research and develop antibody drug conjugates (ADC) using a panel of selected Innate antibodies against an undisclosed target, with a primary focus in Celiac disease.
Business WireInnate Pharma Reports Full Year 2022(1) Financial Results and Business Update
MARSEILLE, France, March 23, 2023--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today reported its consolidated financial results1 for the year ending December 31, 2022. The consolidated financial statements are attached to this press release.
Business WireNumber of Shares and Voting Rights of Innate Pharma as of March 1, 2023
MARSEILLE, France, March 20, 2023--Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") releases its total number of shares outstanding as well as its voting rights as at March 1, 2023:
Business WireInnate Pharma Announces Conference Call and Webcast for Full Year 2022 Financial Results
MARSEILLE, France, March 16, 2023--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Thursday, March 23, 2023 at 2 p.m. CET / 9 a.m. EDT, following the release of its financial results for the full year ending December 31, 2022.
Business WireInnate Pharma Provides Update on Silicon Valley Bank Exposure
MARSEILLE, France, March 13, 2023--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") has learned that Silicon Valley Bank has been closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation ("FDIC") as receiver.
Business WireNumber of Shares and Voting Rights of Innate Pharma as of February 1, 2023
MARSEILLE, France, February 21, 2023--Regulatory News: Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") releases its total number of shares outstanding as well as its voting rights as at February 1, 2023:
Business WireInnate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers
MARSEILLE, France, January 25, 2023--Innate Pharma announces HSR clearance regarding expansion of its collaboration with Sanofi on NK cell engagers
Business WireInnate Pharma Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology
MARSEILLE, France, January 16, 2023--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced today the publication in Nature Biotechnology of preclinical data showing the control of acute myeloid leukemia (AML) cells by a trifunctional NKp46-CD16a-NK cell engager (NKCE) targeting CD123. The studies were conducted by Innate and Sanofi and published in Nature Biotechnology on January 12, 2023.
Business WireSanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology
MARSEILLE, France, December 19, 2022--Sanofi and Innate Pharma expand collaboration for Natural Killer cell therapeutics in oncology
Business WireInnate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022
MARSEILLE, France, December 10, 2022--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today presented data from a preliminary analysis of the TELLOMAK Phase 2 trial demonstrating clinical activity and a favorable safety profile for lacutamab, a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, in patients with advanced Sézary syndrome, a form of T cell lymphoma. The data were presented during the 2022 ASH (American Society Hem
Business WireNumber of Shares and Voting Rights of Innate Pharma as of December 1, 2022
MARSEILLE, France, December 09, 2022--Regulatory News: Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") releases its total number of shares outstanding as well as its voting rights as at December 1, 2022:
Business WireInnate Pharma to present adenosine franchise, IPH5201 and IPH5301 at ESMO IO 2022
MARSEILLE, France, December 01, 2022--Innate Pharma to present adenosine franchise, IPH5201 and IPH5301 at ESMO IO 2022